Pulmonary Interstitial Emphysema Medication

Updated: Jan 04, 2016
  • Author: Abhay J Bhatt, MD, MBBS; Chief Editor: Ted Rosenkrantz, MD  more...
  • Print
Medication

Medication Summary

The principal therapies for pulmonary interstitial emphysema are lateral decubitus positioning, selective intubation and occlusion of the contralateral bronchus, and high-frequency ventilation. However, administration of surfactant administration to premature infants (< 30-32 weeks' gestation) judged to be at risk of developing respiratory distress syndrome may decrease the risk of pulmonary interstitial emphysema.

Next:

Lung Surfactants

Class Summary

These agents prevent the alveoli from collapsing during expiration that results from deficient or ineffective endogenous lung surfactant in neonates. There are two different kinds: Natural and Synthetic.  It is for intratracheal administration only. Surfactant prevents alveoli from collapsing during expiration by lowering the surface tension between air and alveolar surfaces. Surfactant  is used for prophylaxis and treatment of respiratory distress syndrome (RDS) in premature infants.

Previous